Wuxi Abbisko Biomedical Technology

Abbisko Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative small molecule oncology therapies. Headquartered in Shanghai, the company focuses on precision oncology and immuno-oncology to address unmet medical needs globally. Their lead candidate, Pimicotinib (ABSK021), is a highly selective CSF-1R inhibitor currently in Phase 3 trials for tenosynovial giant cell tumors. Abbisko maintains a robust pipeline of internally discovered programs targeting FGFR, EGFR, and KRAS pathways, supported by a proprietary drug discovery platform. The company is listed on the Hong Kong Stock Exchange and has established strategic collaborations with global partners such as Merck KGaA and Eli Lilly.